Moreover, Ga68 PSMA PET-CT has emerged as a predictive imaging modality for patients with advanced prostate cancer who have undergone Lu-PSMA-617 radionuclide therapy, demonstrating its versatility across various stages of the disease [14]. This evidence concerns the gene FOLH1 and prostate carcinoma.